Document is current
Any future updates will be listed below
-
Authors
Nevitt, Sarah J. https://orcid.org/0000-0001-9988-2709
Phillippo, David M. https://orcid.org/0000-0003-2672-7841
Hodgson, Robert https://orcid.org/0000-0001-6962-2893
Welton, Nicky J. https://orcid.org/0000-0003-2198-3205
Dias, Sofia https://orcid.org/0000-0002-2172-0221
-
Funding
Funding for this research was provided by:
Evidence Synthesis Programme (NIHR131946)
- License Information
-
More Information
Article History
Accepted: 21 November 2024
First Online: 3 December 2024
Declarations
:
: This report was commissioned by the NIHR Evidence Synthesis Programme as project number NIHR131946. Please visit the HTA programme website for further project information (). This summary of the EAG report was compiled after NICE issued the Final Guidance. The views and opinions expressed herein are those of the authors and do not necessarily reflect those of NICE or the Department of Health.
: The authors have no conflicts of interest that are directly relevant to the content of this article.
: Not applicable.
: Not applicable.
: Not applicable.
: The data that support this commentary are available on the NICE website ().
: Not applicable.
: SJN and RH were jointly responsible for leading the critical review of the clinical and cost-effectiveness evidence and writing of the EAG report. DMP provided expert advice on matching adjusted indirect treatment comparisons and multi-level network meta-regression that informed the EAG report. All authors contributed to the conception and design of this article. The manuscript was initially drafted by SJN, with input from RH relating to economic modelling content and from SD, DMP and NJW relating to methodology of population-adjusted indirect treatment comparisons. All authors had the chance to comment on draft versions of the manuscript and provided their approval for the final version to be published. SJN acts as the overall guarantor for the article.
